Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06447064

Cancer Loyalty Card Study 2 (CLOCS-2)

Cancer Loyalty Card Study 2 (CLOCS-2) — Recruiting • Oncology • NCT06447064.

📅 25 Mar 2026 ⏱ 4 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06447064
Sponsor
Imperial College London
Start
2026-02-04
ClinicaliQ Trial Snapshot
  • Cancer Loyalty Card Study 2 (CLOCS-2) — Recruiting • Oncology • NCT06447064.
  • Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along….
  • Sponsor: Imperial College London.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working. Therefore, early diagnosis is the most important way to…

Eligibility Snapshot
  • (ALL): * Individuals aged >18 years of age * Individuals must be residing in the United Kingdom at the time of giving informed consent * Individuals must be registered with an NHS GP Practice * Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer). * Individuals must be a primary registered cardholder* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team * Tesco Clubcard * Boots Advantage Card * Provision of written informed consent * Willing and able to comply with all required study activities * The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder… Data sourced from ClinicalTrials.gov. Trial details may change — always check the primary source before clinical decisions.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Oncology · 24 Jun 2026
Mirvetuximab soravtansine is recommended for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with folate receptor-alpha (FRα) positivity—confirm FRα…
View guideline →
Clinical Brief
‘I have chronic cancer but I’m not going to die’ – BBC presenter Maryam Moshiri
Oncology · BBC Health · 07 Sep 2026
Polycythaemia vera should be considered in patients with unexplained blood count abnormalities; routine GP testing can identify the condition before symptomatic presentation…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →
Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →